Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy
NCT07375225 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500
Last updated 2026-01-29
Summary
Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.
Conditions
- Hypercholesterolaemia
Interventions
- DRUG
-
Praluent (Alirocumab)
Alirocumab 300 mg injection
Sponsors & Collaborators
-
Federico II University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-12-01
- Primary Completion
- 2026-12-01
- Completion
- 2027-12-01
- FDA Drug
- Yes
Countries
- Italy
Study Locations
More Related Trials
-
Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol
NCT01959971 ·Status: COMPLETED ·Phase: PHASE1
-
Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)
NCT02023879 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy
NCT01288443 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia
NCT01288469 ·Status: COMPLETED ·Phase: PHASE2
-
Investigating the Effects of Lipid-therapy Intensification With Alirocumab on Endothelial Function, Carotid Arteries, Lipoprotein Particle Subfractions, Inflammation and Post-prandial Lipemia
NCT03559309 ·Status: TERMINATED ·Phase: PHASE4
-
Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)
NCT01709500 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI
NCT03718286 ·Status: COMPLETED ·Phase: PHASE2
-
Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease
NCT03355027 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan
NCT02289963 ·Status: COMPLETED ·Phase: PHASE3
-
Open Label Study of Long Term Safety Evaluation of Alirocumab
NCT01954394 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
NCT01709513 ·Status: COMPLETED ·Phase: PHASE3
-
Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)
NCT03397121 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan
NCT01812707 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia
NCT02715726 ·Status: COMPLETED ·Phase: PHASE3
-
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
NCT03156621 ·Status: COMPLETED ·Phase: PHASE3
-
Education and Awareness Program Targeting the Assessment of Adherence of the Treatment of Dyslipidemia
NCT00557778 ·Status: COMPLETED
-
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
NCT01623115 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
NCT01926782 ·Status: COMPLETED ·Phase: PHASE3
-
Study of A3309 in Patients With Dyslipidemia
NCT01069783 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)
NCT01730040 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene
NCT01604824 ·Status: COMPLETED ·Phase: PHASE2
-
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
NCT03510884 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia
NCT00141141 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
NCT02476006 ·Status: COMPLETED ·Phase: PHASE3
-
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
NCT02890992 ·Status: COMPLETED ·Phase: PHASE2